An observational study in Obstructive Sleep Apnea, sponsored by PranaQ Pte. Ltd.. Completed at 1 site in Taiwan. Open to participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by PranaQ Pte. Ltd. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 90 studies in Sleep Apnea, Obstructive with a site in Taiwan — 26 open to participants now, 27 under way, 3 of them phase 3. Sleep Apnea, Obstructive · Taiwan.
Among the 90 studies in Sleep Apnea, Obstructive with a site in Taiwan, this one is the 12th largest by enrollment of the 32 observational ones that give a count, is one of 8 that started in 2024, is one of 32 observational ones, and was the 63rd registered.
2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.
Browse Sleep Apnea, Obstructive studies →26 of the 90 studies in Sleep Apnea, Obstructive with a site in Taiwan are open now. Recruiting first, the newest first:
Fu Jen Catholic University · Sites in Taiwan
Ages 4–18
National Sun Yat-sen University · Sites in Taiwan
Ages 20–80
National Sun Yat-sen University · Sites in Taiwan
Ages 20+
Novo Nordisk A/S · Sites in Taiwan, United States, Australia and 7 more countries
Ages 18+
Novo Nordisk A/S · Sites in Taiwan, United States, Australia and 7 more countries
Ages 18+
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.
This study: 20 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
90 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 8 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 125 is above the median of 105 across 668 observational studies indexed under Sleep Apnea, Obstructive.
Median enrollment 71 across the 58 interventional studies, 103 across the 32 observational. Of the 38 that completed or were terminated, 4 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 90 have an industry lead sponsor. The 10 most frequent:
PranaQ Pte. Ltd. is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
PranaQ Pte. Ltd. has 4 studies filed under Sleep Apnea, Obstructive — fewer than ten, so there is no comparison to draw.
6 of the studies in Sleep Apnea, Obstructive with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06854497Chiayi Christian HospitalThe Impact of Non-motor Symptom on the Outcome of Stroke Subjects | 2026-12-31 |
| NCT06115018Yi-Ju, LaiThe Efficacy and Maintain Effect of OPR on OSA Patients After Palatal Surgery | 2026-12-31 |
| NCT07603583Kaohsiung Armed Forces General HospitalAssessment of Heart Rate Variability for Predicting Obstructive Sleep Apnea in Patients With Hypertension | 2026-12-31 |
| NCT07192042Taipei Medical University Shuang Ho HospitalInvestigation of Using Non-Wearable Devices to Assess Sleep- Disordered Breathing in Hospitalized Patients With Schizophrenia | 2027-04-30 |
| NCT07805486Fu Jen Catholic UniversityDevelopment of a Multimodal Deep Learning Model for Pediatric Patients | 2027-07-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 90 studies in Sleep Apnea, Obstructive with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A validation study has been designed to assess the performance of a home sleep test device, TipTraQ, for screening sleep apnea. The study involves participants wearing the TipTraQ device on their fingertip during a traditional sleep test, known as polysomnography (PSG), conducted in a sleep center. The performance of the device will then be evaluated by comparing the results from the TipTraQ system with those from the traditional sleep test.
This clinical study is designed to validate TipTraQ, a new sleep screening device developed by PranaQ, for the detection of Sleep Breathing Disorders (SBD), including obstructive sleep apnea-hypopnea syndrome (OSAHS). Given the high prevalence of undiagnosed OSAHS and the cumbersome nature of traditional polysomnography (PSG) - which involves multiple sensors and specialist interpretation - there is a pressing need for more accessible screening tools. TipTraQ aims to meet this need through a wearable device that utilizes photoplethysmography (PPG) and an accelerometer to monitor essential physiological parameters during sleep. This information is then analyzed by an interpretable artificial intelligence (AI) system to estimate key indicators of sleep health such as SpO2, total sleep time (TST), oxygen desaturation index (ODI), and apnea-hypopnea index (AHI).
The study is open-label and non-randomized, planning to recruit 125 subjects. Participants will use the TipTraQ device alongside a companion mobile app, with data analysis supported by AI technology hosted on a cloud server. The primary goal is to assess the accuracy of the TipTraQ system by comparing its output against the gold standard PSG annotations made by sleep experts.
This initiative represents a significant step towards simplifying and democratizing the screening process for sleep disorders, potentially enabling early detection and treatment for a larger segment of the population, thus mitigating personal health risks and broader societal impacts of undiagnosed SBD.
Healthy or people who has indication to conduct polysomnography (PSG).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects from the age of 20 and older that have an indication for an in-lab PSG study in the Duke University Hospital. The subject should be able to understand the study and sign the before being enrolled in the study. During the study period, the subject can withdraw from the study anytime.
Exclusion Criteria:
Subjects with the following medical conditions will be excluded from this study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oxygen Desaturation Index(ODI)
Average desaturation episodes with a decrease in the oxygen saturation of ≥4% or 3% per hour
Time frame: From the start of a single polysomnography study to the end of the recording. Time range from 4hour up to 10 hour.
Apnea Hypopnea Index(AHI)
The combined average number of apneas and hypopneas that occur per hour of sleep
Time frame: From the start of a single polysomnography study to the end of the recording. Time range from 4hour up to 10 hour.
Total Sleep Time(TST)
Total sleep time during the polysomnography (PSG)
Time frame: From the start of a single polysomnography study to the end of the recording. Time range from 4hour up to 10 hour.
Plan to share: No — The study collects mostly physiological signal data, not suitable for IPD
No publications or documents are linked to this record.
Ran from Jun 2024 to primary completion in Apr 2026, 22 months.
Of 36 industry-sponsored observational studies under Sleep Apnea, Obstructive, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 93. This study's 22 months is above that.
Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 14 and three quarters within 63.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion May 2025 → Apr 2026 and completion May 2025 → Apr 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
PranaQ Pte. Ltd.